OverviewSuggest Edit

The UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.
TypePrivate
Founded2011
HQLondon, GB
Websitesynthace.com

Latest Updates

Employees (est.) (Jun 2019)63(+9%)
Revenue (FY, 2013)£581

Key People/Management at Synthace

Tim Fell

Tim Fell

CEO
Christopher Grant Ward

Christopher Grant Ward

Co-Founder
Markus Gershater

Markus Gershater

CSO
Sean Ward

Sean Ward

Founder and CTO
Show more

Synthace Office Locations

Synthace has an office in London
London, GB (HQ)
2 Royal College St
Show all (1)

Synthace Financials and Metrics

Summary Metrics

Synthace's latest funding round in December 2018 was reported to be $25.6 m. In total, Synthace has raised $41.8 m
View all funding rounds

Synthace Revenue

Synthace's revenue was reported to be £581 in FY, 2013
GBP

Revenue (FY, 2013)

581.0

Net income (FY, 2013)

(361.6k)

EBITDA (FY, 2013)

(356.8k)

EBIT (FY, 2013)

(361.6k)

Cash (31-May-2018)

4.9m
GBPFY, 2012FY, 2013

Revenue

581.0

Operating expense total

362.2k

EBITDA

(356.8k)

EBITDA margin, %

(61413%)
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

351.4k103.4k321.7k1.5m245.0k224.3k4.9m

Accounts Receivable

240.0159.9k73.2k9.6k46.6k107.7k

Current Assets

358.1k150.1k481.6k1.6m646.8k883.2k5.8m

PP&E

1.6k14.8k298.8k200.5k265.6k186.8k235.7k
GBPFY, 2012FY, 2013

Net Income

(43.1k)(361.6k)
GBPY, 2018

Financial Leverage

1.2 x
Show all financial metrics

Synthace Online and Social Media Presence

Embed Graph

Synthace News and Updates

Synthace raises $25.6 million to automate bio labs with software

Synthace, a U.K. startup developing an operating system to automate lab work, announced that it has raised $25.6 million in a Series B round.

Synthace reels in $9.6 mln Series A

London-based Synthace, the developer of the Antha operating system for biology, has raised $9.6 million in Series A funding. The investors included White Cloud Capital, Amadeus Capital Partners, Eleven Two Capital, Sofinnova Partners, SOSV and Bioeconomy Capital.

Synthace Blogs

The cell and gene therapy market: why it matters

In the last four years there has been a noticeable push from investors, companies and regulators to bring ever more complicated products, like the CAR-T (Chimeric Antigen Receptor – T cell) therapies, to market. In this blog post we focus on how the market has evolved and what the global ATMP ec…

Synthace Chief Science Officer to Speak at BioProcess International US West

Synthace Senior Executive to address: Closing the loop in bioprocessing with connected lab automation and data integration

Why Synthace is collaborating with Microsoft Research to change the way research on programming biological systems is conducted

By collaborating with Microsoft Research, Synthace hopes that we can employ the expertise Microsoft brings in machine learning, cloud infrastructure and network driven systems biology to accelerate the production of new biological materials and therapeutics.

Closing the Loop in Big Pharma: Perspectives from the Top and Bottom

Back in the early autumn of 2018, we attended 2 events in short succession where the topic of digital transformation in pharma loomed large. Here we compare and contrast these two events, in which we find a commonality between the C-suite and end user on the benefits of digital tools such as aut…

An introduction to Real World Data: An Interview with Dr Susan Shiff

In this interview we sit down with Dr Susan Shiff MBA to discuss how data is being obtained, analysed and used from across the healthcare system to extract insights that deliver meaningful patient outcomes.

How lab automation can deliver a strong return on investment for biotech and pharma companies

Given the importance of measuring a return on investment (ROI) to the continued usage of new software, here are several ways we’ve found that automation delivers a strong ROI to researchers across a variety of biological functions.
Show more

Synthace Frequently Asked Questions

  • When was Synthace founded?

    Synthace was founded in 2011.

  • Who are Synthace key executives?

    Synthace's key executives are Tim Fell, Christopher Grant Ward and Markus Gershater.

  • How many employees does Synthace have?

    Synthace has 63 employees.

  • What is Synthace revenue?

    Latest Synthace annual revenue is £581 .

  • What is Synthace revenue per employee?

    Latest Synthace revenue per employee is £9 .

  • Who are Synthace competitors?

    Competitors of Synthace include International Stem Cell Corporation, ProNAi Therapeutics and DBV Technologies.

  • Where is Synthace headquarters?

    Synthace headquarters is located at 2 Royal College St, London.

  • Where are Synthace offices?

    Synthace has an office in London.

  • How many offices does Synthace have?

    Synthace has 1 office.